Karus Therapeutics Ltd – Product Pipeline Review – Q1 2011 by GlobalMarketsDirect

VIEWS: 17 PAGES: 33

Karus Therapeutics Ltd – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Karus Therapeutics Ltd - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Karus Therapeutics Ltd - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Karus Therapeutics Ltd human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Karus Therapeutics Ltd with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Karus Therapeutics Ltd’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Karus Therapeutics Ltd’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Karus Therapeutics Ltd in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Karus Therapeutics Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opport

More Info
									    Karus Therapeutics Ltd – Product Pipeline Review –
                         Q1 2011
                                                                                          Reference Code: GMDHC1073CDB

                                                                                               Publication Date: MAR 2011




Karus Therapeutics Ltd – Product Pipeline Review – Q1 2011                                  GMDHC1073CDB / Published MAR 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
Karus Therapeutics Ltd – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents                                                                                                         2
List of Tables                                                                                                            4
List of Figures                                                                                                           4
Karus Therapeutics Ltd Snapshot                                                                                           5
    Karus Therapeutics Ltd Overview                                                                                       5
    Key Information                                                                                                       5
    Key Facts                                                                                                             5
Karus Therapeutics Ltd – Research and Development Overview                                                                6
    Key Therapeutic Areas                                                                                                 6
Karus Therapeutics Ltd – Pipeline Review                                                                                  8
    Pipeline Products by Stage of Development                                                                             8
    Pipeline Products – Monotherapy                                                                                       9
Karus Therapeutics Ltd – Pipeline Products Glance                                                                        10
    Karus Therapeutics Ltd–Early Stage Pipeline Products                                                                 10
         Pre-Clinical Products/Combination Treatment Modalities                                                          10
         Discovery Products/Combination Treatment Modalities                                                             11
Karus Therapeutics Ltd – Drug Profiles                                                                                   12
    KAR1141                                                                                                              12
         Product Description                                                                                             12
         Mechanism of Action                                                                                             12
         R&D Progress                                                                                                    12
    KAR2581                                                                                                              13
         Product Description                                                                                             13
         Mechanism of Action                                                                                             13
         R&D Progress                                                                                                    13
    KAR3166                                                                                                              14
         Product Description                                                                                             14
         Mechanism of Action                                                                                             14
         R&D Progress                                                                                                    14
    KAR1139                                                                                                              15
         Product Description                                                                                             15
         Mechanism of Action                                                                                             15
         R&D Progress                                                                                                    15
    KAR3000                                                                                                              16
         Product Description                                                                                             16
         Mechanism of Action                                                                                             16
         R&D Progress                                                                                                    16
Karus Therapeutics Ltd – Pipeline Analysis                                                                               17
    Karus Therapeutics Ltd – Pipeline Products by Therapeutic Class                                                      17
    Karus Therapeutics Ltd - Pipeline Products By Target                                                                 18
    Karus Therapeutics Ltd – Pipeline Products by Route of Administration                                                19
    Karus Therapeutics Ltd – Pipeline Products by Molecule Type                                                          20
Karus Therapeutics Ltd – Locations And Subsidiaries                                                                      21
    Head Office                                                                                                          21
Recent Developments                                                                                                      22
         Feb 18, 2010: Karus Therapeutics Extends Drug Discovery Programme To Target HDAC-6                              22




Karus Therapeutics Ltd – Product Pipeline Review – Q1 2011                                    GMDHC1073CDB / Published MAR 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                 Page(2)
Karus Therapeutics Ltd – Product Pipeline Review



         Feb 18, 2010: Karus Therapeutics Extends Drug Discovery Programme To Target HDAC-6                                   23
         Feb 18, 2010: Karus Therapeutics Extends Drug Discovery Programme To Target HDAC-6                                   24
         Sep 23, 2009: Karus Therapeutics And Queen Mary, University Of London Announce PI3 Kinase Collaboration              25
Financial Deals Landscape                                                                                                     27
    Karus Therapeutics Ltd, Deals Summary, 2004 to 2011                                                                       27
    Karus Therapeutics Ltd Detailed Deal Summary                                                                              28
         Venture Financing                                                                                                    28
         Karus Therapeutics Secures $1.47 Million In Venture Financing                                                        28
         Karus Therapeutics Secures $1.65 Million In Venture Financing                                                        30
         Karus Therapeutics Enters Into Co-Development Agreement With Queen Mary                                              31
Appendix                                                                                                                      32
    Methodology                                                                                                               32
         Coverage                                                                                                             32
         Secondary Research                                                                                                   32
         Primary Research                                                                                                     32
         Expert Panel Validation                                                                                              33
    Contact Us                                                                                                                33
    Disclaimer                                                                                                                33




Karus Therapeutics Ltd – Product Pipeline Review – Q1 2011              
								
To top